Detection of FRα can be used postoperatively to detect residual tumors, to screen blood samples for cancers, to detect malignancy via immunohistochemistry, to evaluate expression correlating to prognosis/chemotherapy resistance, or to enhance existing therapies. This evidence concerns the gene FOLR1 and cancer.